Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial

Manesh R. Patel | Timothy N Murphy | Deepak L. Bhatt | Raghava R. Gollapudi | S. Oparil | M. Vaduganathan | H. Dauerman | A. Kirtane | G. Bakris | A. Denktas | S. Parikh | G. Dangas | M. Leon | M. Buchbinder | M. Shishehbor | R. Townsend | R. D’Agostino | L. Mauri | I. Moussa | M. Fahy | D. Kandzari | H. Gurm | J. Reiner | G. Vetrovec | M. Creager | M. Esler | S. David | R. Waksman | S. Nathan | Yale Wang | K. Ziada | M. Negoita | William E. Downey | B. Negus | D. Cohen | S. Waxman | J. Flack | S. Marso | M. Razavi | H. Aronow | M. Dunlap | B. Katzen | Sidney A. Cohen | K. Rocha-Singh | J. Preibisz | James W Choi | S. Kinlay | D. Slovut | T. Todoran | J. Schindler | L. Gruberg | R. Gulati | E. Gnall | M. Robbins | R. Kovach | T. Shimshak | Mitchell Silver | G. Petrossian | E. Marchena | D. Brown | C. Devireddy | M. Leon | O. Randall | Nilesh J. Goswami | T. Scott | E. Chung | K. Benzuly | Sandeep Brar | Somjot S. Brar | Anuj Gupta | F. Rader | A. Babaev | Jasvindar Singh | Tayo A. Addo | E. Mazzaferri | Anjan Gupta | M. Ghali | R. Townsend | R. Kipperman | John Angle | Renato M. Santos | D. Calhoun | Jeffrey W Hastings | F. Zidar | David P. Lee | Vanessa Debruin | Mark Davies | D. Anderson | B. Paulus | B. Katzen | Z. Abbud | P. Casale | Sheldon Chaffer | D. Fisher | Mark J. Goodwin | Samuel Mann | Fadi Matar | Farrel Mandelsohn | Kirikumar Patel | Alex Powell | J. Reilly | Michael Ring | Kevin L. Rogers | N. Ruggiero | William Little | K. Singh | Rick G Stoufer | Paul Teirsten | R. Wilkins | M. Patel | Martin Leon | Ralph A. D’Agostino | Mark Goodwin | David Brown | R. Waksman | Eric Gnall

[1]  B. Davis,et al.  Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis , 2022, The lancet. Diabetes & endocrinology.

[2]  K. Kario,et al.  Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial , 2022, The Lancet.

[3]  Deepak L. Bhatt,et al.  Renal Denervation for Hypertension: A Systematic Review and Meta-Analysis of Randomized, Blinded, Placebo-Controlled Trials. , 2021, JACC. Cardiovascular interventions.

[4]  R. Collins,et al.  Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis , 2021, The Lancet.

[5]  Dave L Dixon,et al.  Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. , 2021, Journal of the American College of Cardiology.

[6]  P. Gosse,et al.  12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. , 2020, JACC. Cardiovascular interventions.

[7]  Manesh R. Patel,et al.  Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial , 2020, The Lancet.

[8]  S. Solomon,et al.  Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). , 2020, JAMA cardiology.

[9]  A. Kirtane,et al.  The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. , 2020, JACC. Cardiovascular interventions.

[10]  Deepak L. Bhatt,et al.  Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes. , 2019, The New England journal of medicine.

[11]  Deepak L. Bhatt,et al.  Sham-Controlled Randomized Trials of Catheter-Based Renal Denervation in Patients With Hypertension. , 2019, Journal of the American College of Cardiology.

[12]  David A Calhoun,et al.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.

[13]  Spiros C. Denaxas,et al.  Time spent at blood pressure target and the risk of death and cardiovascular diseases , 2018, PloS one.

[14]  S. Pocock,et al.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial , 2018, The Lancet.

[15]  Neil Chapman,et al.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial , 2018, The Lancet.

[16]  Per Winkel,et al.  When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts , 2017, BMC Medical Research Methodology.

[17]  Neil Chapman,et al.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.

[18]  Eyal Oren,et al.  Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2017, Lancet.

[19]  Deepak L. Bhatt,et al.  Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension　- Insights From the SYMPLICITY HTN-3 Trial. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[20]  Deepak L. Bhatt,et al.  Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. , 2015, Hypertension.

[21]  R. Whitbourn,et al.  Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. , 2015, Journal of the American College of Cardiology.

[22]  Deepak L. Bhatt,et al.  An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. , 2015, Journal of the American Society of Hypertension : JASH.

[23]  Deepak L. Bhatt,et al.  12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. , 2015, Journal of the American College of Cardiology.

[24]  C. May,et al.  Reinnervation of Renal Afferent and Efferent Nerves at 5.5 and 11 Months After Catheter-Based Radiofrequency Renal Denervation In Sheep , 2015, Hypertension.

[25]  Deepak L. Bhatt,et al.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.

[26]  Deepak L. Bhatt,et al.  Non-adherence to cardiovascular medications. , 2014, European heart journal.

[27]  Deepak L. Bhatt,et al.  Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. , 2014, Journal of the American College of Cardiology.

[28]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[29]  Deepak L. Bhatt,et al.  Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial , 2012, Clinical cardiology.

[30]  Deepak L. Bhatt,et al.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. , 2012, European heart journal.

[31]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[32]  K. Wittkowski,et al.  Analytical approaches to reporting long-term clinical trial data , 2008, Current medical research and opinion.

[33]  Roger B. Davis,et al.  Sham device v inert pill: randomised controlled trial of two placebo treatments , 2006, BMJ : British Medical Journal.